Cost-effectiveness analysis of artificial intelligence (AI) in earlier detection of liver lesions in cirrhotic patients at risk of hepatocellular carcinoma in Italy.

Journal: Journal of medical economics
Published Date:

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer-related death. Cirrhosis is a major contributing factor, accounting for over 90% of HCC cases. With the high mortality rate of HCC, earlier detection of HCC is critical. When added to magnetic resonance imaging (MRI), artificial intelligence (AI) has been shown to improve HCC detection. Nonetheless, to date no cost-effectiveness analyses have been conducted on an AI tool to enhance earlier HCC detection. This study reports on the cost-effectiveness of detection of liver lesions with AI improved MRI in the surveillance for HCC in patients with a cirrhotic liver compared to usual care (UC).

Authors

  • L Maas
    Radiomics.bio, Liege, Belgium.
  • C Contreras-Meca
    Radiomics.bio, Liege, Belgium.
  • S Ghezzo
    radiomics.bio, Liege, Belgium.
  • F Belmans
    radiomics.bio, Liege, Belgium.
  • A Corsi
    radiomics.bio, Liege, Belgium.
  • J Cant
    radiomics.bio, Liege, Belgium.
  • W Vos
    Radiomics.bio, Liege, Belgium.
  • Maciej Bobowicz
    2nd Department of Radiology, Medical University of Gdansk, Gdansk, Poland.
  • M Bobowicz
    2nd Division of Radiology, Medical Univeristy of Gdańsk, Gdańsk, Poland.
  • M Rygusik
    2nd Division of Radiology, Medical Univeristy of Gdańsk, Poland.
  • Dariusz Krzysztof Laski
    Department of Oncological, Transplant and General Surgery, Medical Univeristy of Gdańsk, Poland.
  • D K Laski
    Department of Oncological, Transplant and General Surgery, Medical Univeristy of Gdańsk, Gdańsk, Poland.
  • L Annemans
    Ghent University, Faculty of Medicine and Health Sciences, Ghent, Belgium.
  • M Hiligsmann
    Department of Health Services Research, Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands.